U.S. ARMY MED. RESEARCH ACQUISITION ACT, MCMR-RMA (PGI-2), FORT DETRICK BLDG. 820, FREDERICK MD 21702-5014

A -- PYRIDOSTIGMINE BROMIDE STUDIES PERSIAN GULF WAR ILLNESSES SOL DAMD17-95-#-0009 MCMR-RMA (PGI-2) DUE 082395 POC CRAIG D. LEBO, 301-619-2036 (i) DAMD17-95-#-0009; (ii) Award will be made in accordance with the guidelines of the R&D Streamlined Contracting procedure outlined in DFARS 235.700O; (iii) Supplemental package; (iv) availability of supplemental; (v) All mandatory terms, clauses and provision in DFARS 235.7006 and the following optional items are incorporated by reference : (B.6, C.3, E.3, F.1, G.1,G.4, I.43, I.46 to I.51, I.53, I.55, I.56, I.63, I.64, I.70, I.75, I.78, I.79, I.86, I.88, I.89,I.94, I.97, I.98, I.104, I.106. I.107, I.124, I.125, I.127 to I.129, I.160, I.164; (vi) Clauses and provisions are those in effect through FAC 90-24, dated 15 DEC 94 and DAC 91-6, dated 27 May 1994; (vii) The standard evaluation factors at Section M apply to this RDSS with the following exceptions: Factor M.1 is deleted in its entirety and factor M.2 (ii) A(1) is supplemented - ''As part of the technical approach an assessment of whether the proposal clearly addresses a relevant and significant military problem that can be solved by research and development studies.'' Factor M.2 (ii) A(2) is supplemented -''Applicants must have demonstrated expertise in epidemiology, neurobiology, toxicology or pharmacology and must have no financial relationship with any company that manufactures a product that may be addressed in the study''; (viii) The resultant contract will normally require the timely delivery of several reports during the research effort, specifically a quarterly financial report, a Mid-Term Scientific Report and a Final Report. Additionally, publication of study results in peer reviewed scientific journals is imperative; (ix) A cost reimbursement contract is anticipated. However, the government reserves the right to award grants or cooperative agreements as a result of this solicitation. (x) The period of performance should not exceed three years. Specific products and delivery dates will be negotiated with each successful grantee; (xi) No preproposal conference is planned; (xii) No small business or other set-asides apply to this action. (xiii) Technical and cost proposals are due no later than 2:00 pm Eastern Daylight Time 23 August 1995, to Building 820, Fort Detrick, Frederick, Maryland 21702-5014 M/F DAMD17-95-#-0009; (xiv) Proposals shall be submitted in an original and 19 copies. (xv) No proposal page limit is mandated except that indicated in Section L.24 (see also FAR 52.215-7); Multiple awards are anticipated; Point of Contact Craig D. Lebo, U.S. Army Medical Research Acquisition Activity, Building 820, Fort Detrick, Frederick, Maryland 21702- 5014 (telephone 301-619-2036, fax, 301-619-2937), email, craig_lebo@ftdetrck-ccmail.army.mil; (xviii) There are no applicable CBD notes; (xx) Statement of work: The U.S. Army Medical Research and Materiel Command (USAMRMC), on behalf of the Departments of Defense, Veterans Affairs, and Health and Human Services Cooperative Research Program, is supporting studies of the health consequences of the use of pyridostigmine bromide alone as a pretreatment against nerve agents, and in combination with possible exposure(s) to pesticides, other organophosphorus compounds, carbamates or other relevant chemicals. Proposals are sought that are designed to determine whether the use of pyridostigmine bromide alone as a pretreatment against nerve agents, or combined with exposures to pesticides, other organophosphorus compounds, carbamates or other relevant chemicals would result in increased toxicity. Proposals are sought which include the chronic health effects of sub-toxic exposures (alone or in combinations) to the compounds mentioned. Proposed studies can utilize appropriate valid animal models or non animal models, including in-vitro systems. Proposed studies that include animal models will be approved by an institutional animal care and use committee. Proposed studies will conform to requirements of good laboratories practices (GLP) compliant toxicological research. Proposals are sought which retrospectively study the nature of illnesses suffered by members of the Armed Services who served in the Persian Gulf War and the extent to which these illnesses are associated with the use of pyridostigmine bromide or other medications or special immunizations, and exposure to pesticides, organophophates, or carbamates.(0142)

Loren Data Corp. http://www.ld.com (SYN# 0004 19950523\A-0004.SOL)